Abstract:Humans are exposed to numerous compounds daily, some of which have adverse effects on health. Computational approaches for modeling toxicological data in conjunction with machine learning algorithms have gained popularity over the last few years. Machine learning approaches have been used to predict toxicity-related biological activities using chemical structure descriptors. However, toxicity-related proteomic features have not been fully investigated. In this study, we construct a computational pipeline using machine learning models for predicting the most important protein features responsible for the toxicity of compounds taken from the Tox21 dataset that is implemented within the multiscale Computational Analysis of Novel Drug Opportunities (CANDO) therapeutic discovery platform. Tox21 is a highly imbalanced dataset consisting of twelve in vitro assays, seven from the nuclear receptor (NR) signaling pathway and five from the stress response (SR) pathway, for more than 10,000 compounds. For the machine learning model, we employed a random forest with the combination of Synthetic Minority Oversampling Technique (SMOTE) and Edited Nearest Neighbor (ENN) method (SMOTE+ENN), which is a resampling method to balance the activity class distribution. Within the NR and SR pathways, the activity of the aryl hydrocarbon receptor (NR-AhR), and mitochondrial membrane potential (SR-MMP) were two of the top-performing twelve toxicity endpoints with AUCROCs of 0.90 and 0.92, respectively. The top extracted features for evaluating compound toxicity were analyzed for enrichment to highlight the implicated biological pathways and proteins. We validated our enrichment results for the activity of the AhR using a thorough literature search. Our case study showed that the selected enriched pathways and proteins from our computational pipeline are not only correlated with AhR toxicity but also form a cascading upstream/downstream arrangement. Our work elucidate significant relationships between protein and compound interactions computed using CANDO and the associated biological pathways to which the proteins belong for twelve toxicity endpoints. This novel study uses machine learning not only to predict and understand toxicity but also elucidates therapeutic mechanisms at a proteomic level for a variety of toxicity endpoints.

Quantitative Proteomics for Drug Toxicity.

Research progress in drug toxicology based on systems biology

Genomic and Proteomic Approaches for Predicting Toxicity and Adverse Drug Reactions.

Systems toxicology: applications of toxicogenomics, transcriptomics, proteomics and metabolomics in toxicology

Recent advances in the quantification of drug metabolizing enzymes and transporters by proteomic approach

Quantitative knowledge-based analysis in compound safety assessment

A systematic identification of multiple toxin-target interactions based on chemical, genomic and toxicological data.

Target identification of natural and traditional medicines with quantitative chemical proteomics approaches.

Chemoproteomics: Towards Global Drug Target Profiling

Application of the Technology of Proteomics in Hepatotoxicity of TCM

Quantitative proteomics for cancer biomarker discovery.

Metabonomics: its potential as a tool in toxicology for safety assessment and data integration

Recent Advances in Omics, Computational Models, and Advanced Screening Methods for Drug Safety and Efficacy

Advancements in Quantitative Proteomics Technologies Based on Mass Spectrometry

Chemical Proteomics: Terra Incognita for Novel Drug Target Profiling

Toxicogenomics and drug discovery: will new technologies help us produce better drugs?

Identifying Protein Features and Pathways Responsible for Toxicity Using Machine Learning and Tox21: Implications for Predictive Toxicology

Proteomics in Biomarker Discovery and Drug Development

Protein target discovery of drug and its reactive intermediate metabolite by using proteomic strategy

Proteomics in Computer-Aided Drug Design